Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,473.95 +277.76 (+0.45%) CMC Crypto 200
1,274.97 -8.81 (-0.69%)
Swedish Orphan Biovitrum AB (publ) (SOBIS.XC)
| Previous close | 279.60 |
| Open | 279.90 |
| Bid | 274.20 x 0 |
| Ask | 278.20 x 0 |
| Day's range | 279.60 - 279.60 |
| 52-week range | 201.40 - 290.60 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 95.027B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 44.24 |
| EPS (TTM) | 6.32 |
| Earnings date | 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEuropean Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity. Children, adolescents, and adults can experience non-haemophilia factor VIII activity levels (above 40%) for a significant part of the week with once-weekly prophylaxis, reaching trough level
GlobeNewswireSobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 – June 4, 2024. Sobi’s commitment to delivering innovative treatments for people living with hematological diseases is seen in global studies span
- GlobeNewswire
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a potential therapeutic option in patients with Macrophage Activation Syndrome (MAS). Emapalumab is a fully human, anti-IFNγ monoclonal antibody that binds free and receptor-bound IFNγ, neutralizing its biological activity.
